Nascent Biotech Inc. (NBIO) financial statements (2022 and earlier)
Company profile
| Business Address |
6330 NANCY RIDGE DR. SAN DIEGO, CA 92121 |
| State of Incorp. | NV |
| Fiscal Year End | March 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2020 TTM | 3/31/2020 | 3/31/2019 | 3/31/2018 | 3/31/2017 | 3/31/2016 | 3/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 55 | 3 | 131 | 117 | 130 | 573 | 108 | ||
| Cash and cash equivalents | 55 | 3 | 131 | 117 | 130 | 573 | 108 | ||
| Receivables | 60 | 60 | |||||||
| Prepaid expense | 18 | 2 | |||||||
| Other undisclosed current assets | (60) | (60) | |||||||
| Total current assets: | 73 | 3 | 131 | 117 | 130 | 573 | 110 | ||
| Noncurrent Assets | |||||||||
| Other undisclosed noncurrent assets | 770 | 828 | 828 | ||||||
| Total noncurrent assets: | 770 | 828 | 828 | ||||||
| TOTAL ASSETS: | 73 | 3 | 131 | 117 | 900 | 1,401 | 938 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 762 | 853 | 526 | 203 | (19) | (19) | 1,281 | ||
| Accounts payable | 853 | 526 | 203 | 152 | 2,339 | 1,276 | |||
| Accrued liabilities | 5 | ||||||||
| Other undisclosed accounts payable and accrued liabilities | 762 | (171) | (2,358) | ||||||
| Debt | 110 | 50 | (60) | ||||||
| Derivative instruments and hedges, liabilities | 0 | 4 | 6 | ||||||
| Due to related parties | 207 | 1,284 | 88 | 1 | |||||
| Other undisclosed current liabilities | 226 | 693 | 245 | 2,985 | 1,797 | ||||
| Total current liabilities: | 1,305 | 2,879 | 614 | 203 | 166 | 2,970 | 3,085 | ||
| Noncurrent Liabilities | |||||||||
| Other undisclosed noncurrent liabilities | (19) | (19) | 60 | ||||||
| Total noncurrent liabilities: | (19) | (19) | 60 | ||||||
| Other undisclosed liabilities | 19 | 19 | |||||||
| Total liabilities: | 1,305 | 2,879 | 614 | 203 | 166 | 2,970 | 3,145 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | (1,232) | (2,876) | (482) | (86) | 734 | (1,569) | (2,207) | ||
| Preferred stock | 0 | 0 | |||||||
| Common stock | 91 | 45 | 33 | 28 | 23 | 22 | 18 | ||
| Additional paid in capital | 16,856 | 13,917 | 12,319 | 11,350 | 9,954 | 8,790 | 4,007 | ||
| Accumulated deficit | (18,179) | (16,838) | (12,833) | (11,465) | (9,243) | (10,380) | (6,231) | ||
| Total stockholders' equity: | (1,232) | (2,876) | (482) | (86) | 734 | (1,569) | (2,207) | ||
| TOTAL LIABILITIES AND EQUITY: | 73 | 3 | 131 | 117 | 900 | 1,401 | 938 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2020 TTM | 3/31/2020 | 3/31/2019 | 3/31/2018 | 3/31/2017 | 3/31/2016 | 3/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 3,000 | |||||||
| Cost of revenue (Cost of Goods and Services Sold) | (2,000) | (333) | ||||||
| Gross profit: | (2,000) | 2,667 | ||||||
| Operating expenses | (118) | (615) | (1,369) | (2,222) | (1,573) | (4,718) | (2,123) | |
| Other undisclosed operating income (loss) | (3,963) | (2,833) | 2,000 | 333 | 847 | |||
| Operating income (loss): | (4,080) | (3,447) | (1,369) | (2,222) | 1,427 | (3,871) | (2,123) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (231) | (557) | 0 | 0 | (50) | (278) | (29) | |
| Interest and debt expense | (202) | (87) | 145 | (1,574) | (24) | |||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (87) | |||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (4,600) | (4,091) | (1,369) | (2,221) | 1,522 | (5,722) | (2,176) | |
| Other undisclosed income (loss) from continuing operations before income taxes | 87 | 87 | (145) | |||||
| Income (loss) from continuing operations before income taxes: | (4,514) | (4,004) | (1,369) | (2,221) | 1,377 | (5,722) | (2,176) | |
| Income tax expense | (240) | |||||||
| Net income (loss): | (4,514) | (4,004) | (1,369) | (2,221) | 1,137 | (5,722) | (2,176) | |
| Other undisclosed net income (loss) attributable to parent | 202 | (0) | 1,574 | 24 | ||||
| Net income (loss) available to common stockholders, diluted: | (4,312) | (4,004) | (1,369) | (2,222) | 1,137 | (4,149) | (2,152) | |
Comprehensive Income ($ in thousands)
| 12/31/2020 TTM | 3/31/2020 | 3/31/2019 | 3/31/2018 | 3/31/2017 | 3/31/2016 | 3/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (4,514) | (4,004) | (1,369) | (2,221) | 1,137 | (5,722) | (2,176) | |
| Comprehensive income (loss), net of tax, attributable to parent: | (4,514) | (4,004) | (1,369) | (2,221) | 1,137 | (5,722) | (2,176) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.